Humana Inc. (HUM) is a leading health and well-being company based in Louisville, Kentucky. Founded in 1961 as a nursing home company, it has grown and evolved over time to become one of the largest and most dynamic companies in the American health insurance sector. Today, it provides health insurance and wellness solutions to millions of people throughout the United States.
Humana offers a wide range of insurance products and complementary services. These include medical insurance, specialty products like dental and vision coverage, and Medicare and Medicaid products. The company's primary focus is on health and wellness, as reflected in their company mission: to help people achieve lifelong well-being. To that end, Humana has developed a range of offerings aimed at preventing illness and promoting health, from fitness programs to home health services.
Humana's innovative approach to health care has set it apart in the industry. The company is a leader in value-based care, a health care delivery model in which doctors and hospitals are paid based on patient health outcomes rather than services rendered. Through this model, Humana aims to improve the quality of care for its members while reducing health care costs.
One of the defining aspects of Humana's corporate culture is its commitment to social responsibility. The company involves itself in various charitable endeavors and community outreach programs. It is part of the Bold Goal initiative, which aims to improve community health by 20% by 2020, and it also has a program called Humana At Home that provides home-based care for chronically ill or disabled patients.
Humana is not only a chief employer in Louisville but also has a significant presence in many other communities across the country. Over the years, the company has received multiple accolades, including being named among America’s most JUST companies according to JUST Capital and Forbes magazine.
Financially, Humana is a significant player in the healthcare sector, with revenues in the tens of billions of dollars annually. It is publicly traded on the New York Stock Exchange under the symbol HUM and is part of the Fortune 500 list of the largest corporations in the U.S.
In conclusion, Humana Inc. is more than just a health insurance company. It is a pioneer in transforming the health sector with a focus on proactive wellness, a leader in adopting value-based healthcare delivery models, and a committed supporter of the communities it serves.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Humana Inc. (NYSE:HUM) has an average "Moderate Buy" rating from thirty-two research firms, with an average one-year price target of $469.57. Following strong third-quarter earnings and a raised 2026 adjusted EPS outlook, several brokerages increased their price targets. The company also recently declared a quarterly dividend of $0.8850.
Securitize Holdings (NYSE: SECZ) shares surged after the company reported third-quarter revenue of $18.61 million, beating analyst expectations. Despite a wider-than-expected per-share loss, much of it was attributed to non-cash expenses. The company also announced a $50 million share repurchase plan and the acquisition of River Credit Labs (River One), alongside reaching a record $5 billion in average tokenized assets.
The nation's largest health insurers reported a record $449 billion in revenue and $9.2 billion in profits in Q3, exceeding analyst expectations. This growth was driven by strategies focused on charging more, covering less, and shifting financial risk, rather than expanding access or improving services. While investors celebrate, these practices raise concerns about healthcare affordability and accessibility for Americans, as evidenced by declining enrollment in fully insured plans and rising costs for consumers.
UnitedHealth Group (NYSE:UNH) reported strong Q3 results on October 13, surpassing analyst forecasts for adjusted earnings per share and improving its medical care ratio. While total membership was slightly below expectations, reflecting a strategy to prioritize profitable business, the company raised its full-year earnings outlook. The positive report offers insights into the broader healthcare sector, though regulatory scrutiny and ongoing medical cost trends remain factors to monitor.
Humana Inc. reported better-than-expected third-quarter results with a narrower loss and raised its fiscal 2026 adjusted earnings per share guidance. Following the announcement, several analysts from Cantor Fitzgerald, Barclays, Guggenheim, and Piper Sandler maintained their "Overweight" or "Buy" ratings and increased their price targets for Humana shares. The company's President and CEO, Jim Rechtin, expressed satisfaction with the positive results and improved financial performance.
Humana has initiated cash tender offers to repurchase up to $1.5 billion of eight series of its senior notes, excluding accrued coupon payments, with a specific cap of $800 million for its 2031 notes. This move aims to reduce the company's outstanding debt and borrowing costs, offering note holders a cash option at a price to be determined on November 16, 2026. Acceptance of tenders is subject to proration and priority rules, and Humana retains the right to modify the offer terms.
Brown & Brown's 2027 Employer Health and Benefits Strategy Survey indicates that rising healthcare costs are compelling employers to prioritize organizational cost control over employee benefits affordability. While employers are implementing aggressive cost-containment measures like benefits audits and PBM evaluations, they also maintain a commitment to employee well-being and mental health support. The survey also highlights the challenge of balancing GLP-1 medication coverage with budget constraints.
Healthcare Services Group (NASDAQ:HCSG) has received a "Moderate Buy" rating from Wall Street analysts, with an average 12-month price target of $26.67. The company's recent quarterly earnings of $0.36 per share surpassed estimates, though revenue was slightly below expectations and EPS decreased year-over-year. Insider selling by an executive was also noted.